Pharmacies play a crucial role in the healthcare system by ensuring that patients have access to necessary medications and access to expanded care. However, over the years pharmacies have dealt with major financial challenges due to a complex reimbursement system–particularly the Dirty, Insufferable, Ridiculous, ahem, Direct and Indirect Remuneration (DIR) fees. Fortunately it seems that the government is beginning to address these, and in 2024 the landscape of DIR fees for pharmacies is set to change significantly. These changes offer potential relief and increased transparency. In this blog post, we will explore the forthcoming changes and their implications for pharmacies.
A Shift Towards Transparency
Historically, as we are sure you are all aware, these fees have been about as transparent as that guy who always stands directly in front of the television (get out of the way, Greg!). One of the significant changes anticipated in 2024 is a push towards greater transparency in DIR fees. The Centers for Medicare and Medicaid Services (CMS) has proposed regulations requiring Pharmacy Benefit Managers (PBMs) to disclose detailed information about DIR fees such as the timing, calculation methods, and purposes. This increased transparency will enable pharmacies to better understand how DIR fees impact their financial performance and develop strategies to mitigate their impact.
Reduction in Retroactive DIR Fees
Everyone knows that the only thing that should be retro-active is disco. Another positive development on the horizon is the CMS's proposal to eliminate retroactive DIR fees. Currently, pharmacies are hit with substantial fees based on performance metrics retroactively assessed at the end of a contract year. This system has made it challenging for pharmacies to accurately estimate their reimbursement rates, resulting in financial uncertainty. With the elimination of retroactive DIR fees, pharmacies will have a clearer understanding of their reimbursement rates in real-time, allowing for improved financial planning and stability. Now it’s time to dance.
Enhanced Reimbursement Models
In 2024, pharmacies may also benefit from new reimbursement models that could replace the current structure, which heavily relies on DIR fees. The CMS is exploring the possibility of a point-of-sale (POS) pharmacy reimbursement model. Under this model, reimbursement rates would be determined at the time of purchase, allowing pharmacies to receive fair compensation for their services without the uncertainty associated with DIR fees. In turn, this will also allow pharmacies more opportunity to track reimbursements of different NDCs across a GPI to maximize profit–without the concern of those DIR fees afterward.
Conclusion
The upcoming changes in DIR fees for pharmacies in 2024 hold the promise of increased transparency, reduced retroactive fees, and the potential for enhanced reimbursement models, finally. These changes are essential steps towards creating a fairer reimbursement system that ensures the viability and sustainability of pharmacies in the ever-evolving healthcare landscape. While the specific details of the new regulations are yet to be finalized, the proposed shifts indicate a positive trajectory for pharmacies, fostering financial stability and allowing them to focus on providing quality care to patients–including clinical care. As the industry adapts to these changes, pharmacies should stay informed and proactively adjust their business strategies to optimize their financial outcomes in the years to come. DIR fees can go to hell, we will be going to our nearest independent pharmacy.
Comments